Bench to Bedside: A Roadmap for Developing Novel Gene Therapies
TherageniX team – Stefania and Anand, together with our inventor, James Dixon from the University of Nottingham have authored an article on how to translate novel gene therapy research from academia to the clinic for patients in need. Please have a look at this peer-reviewed article published in International Biopharmaceutical Industry (Volume 7 Issue 3)
TherageniX appoints Regenerative engineering pioneer, Prof. Cato Laurencin to its Scientific Advisory Board
Biomaterials, stem cells and gene therapy expert, and orthopaedic surgeon joins TherageniX’s scientific Advisory Board to advance product development and advise on company strategy. TherageniX (www.theragenix.health) , an early-stage biotechnology company pioneering the use of gene therapy for tissue regeneration announced that it has appointed Prof. Cato Laurencin to its Scientific Advisory Board. Dr. Cato […]
Non-viral gene therapies: GETting growth-factor-based healing right in orthopaedics
Anand Nandakumar (our CEO) and Dr. James Dixon (inventor) wrote an article on the use of non-viral gene therapies for bone regeneration. This has been published by Innovations in Pharmaceutical Technology. Click here to read the article. Innovations in Pharmaceutical Technology, Spring 2024, pages 30-34. © Samedan Ltd
TherageniX appoints Professor Ben Ollivere to its Scientific Advisory Board
Experienced Orthopaedic surgeon, researcher, and academic joins TherageniX’s scientific Advisory Board to help accelerate product development. TherageniX (www.theragenix.health) , an early-stage biotechnology company pioneering the use of gene therapy for tissue regeneration announced that it has appointed Prof. Ben Ollivere from the University of Nottingham to its Scientific Advisory Board. Professor Ollivere works at the […]
TherageniX is looking for a Scientific Project Manager
Job Title Scientific Project Manager Job Type Fixed-Term 1 year (with possibility of extension), Full-time Hours per week 37.5 per week Location Remote with occasional travel within the UK Pay £45,000 – £50,000 per annum plus benefits Start Date January 2024 About Us TherageniX is an early-stage biotechnology company focused on using a gene therapy […]
TherageniX and University of Nottingham Awarded £995K Innovate UK Grant to Develop Powdered Gene Therapy for Bone Regeneration
London, UK, and Nottingham, UK, 31 August 2023: TherageniX, a University of Nottingham spin out pioneering a dry powder gene therapy formulation for bone graft augmentation, and its collaborator, the University of Nottingham, have been awarded a £995,000 grant from Innovate UK, the UK’s innovation agency. The funding will support the development of the Company’s […]
THERAGENIX: SPIN-OUT COMPANY ESTABLISHED TO PROVIDE GENE THERAPY IN BONE REPAIR SURGERY
Our partner, U of N also shared their perspective on the launch of TherageniX, a spin-out company – TherageniX to deliver gene therapy as part of bone repair surgery. The innovative approach aims to enhance the healing process by introducing genes that promote bone regeneration. TherageniX establishment signifies a significant step towards translating research findings into practical applications, […]
INTRODUCING THERAGENIX: TISSUE REGENERATION THROUGH GENES
Disease, injuries and aging can damage body tissues. There is an unmet need for novel therapies to enable tissue repair and regeneration. The use of gene therapy to provide biological cues to boost the body’s response has been shown to aid regeneration of skin, bone, muscle and cartilage. TherageniX, another venture from NLC, delivers genes […]